Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.

IF 0.8 Q4 UROLOGY & NEPHROLOGY

Urology Annals Pub Date : 2025-07-01 Epub Date: 2025-07-18 DOI:10.4103/ua.ua_21_25

Peerapon Sangthong, Nattapong Binsri, Sarayut Kanjanatarayon, Weerayut Wiriyabanditkul, Thanisorn Pattanasuwon, Satit Siriboonrid

{"title":"Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer.","authors":"Peerapon Sangthong, Nattapong Binsri, Sarayut Kanjanatarayon, Weerayut Wiriyabanditkul, Thanisorn Pattanasuwon, Satit Siriboonrid","doi":"10.4103/ua.ua_21_25","DOIUrl":null,"url":null,"abstract":"Purpose: We evaluated the clinical outcome of high-risk prostate cancer patients receiving radical prostatectomy (RP) or radiotherapy (RT).Materials and methods: Patients were classified as high-risk prostate cancer and received definitive treatment between 2013 and 2023. Patients with previous pelvic RT and incomplete medical record were excluded. The primary outcomes were progression-free survival (PFS) and distant metastasis-free survival (MFS). The secondary outcomes were factors for progression and metastasis.Results: Of 244 patients analyzed (89 RP and 155 RT); the estimated 10-year PFS was 49.9% in the RP and 75.5% in the RT (P = 0.013). No significant difference was seen in the distant MFS (P = 0.177) and overall survival (P = 0.052). Univariate and multivariate were analyzed; the factor for progress or metastasis was initial prostate-specific antigen.Conclusion: Our data demonstrated that RT offers superiority over RP in PFS, whereas distant metastasis was similar.","PeriodicalId":23633,"journal":{"name":"Urology Annals","volume":"17 3","pages":"144-148"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366844/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Annals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ua.ua_21_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We evaluated the clinical outcome of high-risk prostate cancer patients receiving radical prostatectomy (RP) or radiotherapy (RT).

Materials and methods: Patients were classified as high-risk prostate cancer and received definitive treatment between 2013 and 2023. Patients with previous pelvic RT and incomplete medical record were excluded. The primary outcomes were progression-free survival (PFS) and distant metastasis-free survival (MFS). The secondary outcomes were factors for progression and metastasis.

Results: Of 244 patients analyzed (89 RP and 155 RT); the estimated 10-year PFS was 49.9% in the RP and 75.5% in the RT (P = 0.013). No significant difference was seen in the distant MFS (P = 0.177) and overall survival (P = 0.052). Univariate and multivariate were analyzed; the factor for progress or metastasis was initial prostate-specific antigen.

Conclusion: Our data demonstrated that RT offers superiority over RP in PFS, whereas distant metastasis was similar.

Abstract Image

查看原文本刊更多论文

前列腺根治术与外束放疗治疗高危前列腺癌的比较。

目的：评价高危前列腺癌患者接受根治性前列腺切除术（RP）或放射治疗（RT）的临床疗效。材料和方法：患者被分类为高危前列腺癌，并于2013年至2023年接受最终治疗。排除既往盆腔放疗和病历不完整的患者。主要结局是无进展生存期（PFS）和无远处转移生存期（MFS）。次要结局是进展和转移的因素。结果：244例患者中，RP 89例，RT 155例；估计10年PFS在RP组为49.9%，在RT组为75.5% （P = 0.013）。远端MFS （P = 0.177）和总生存率（P = 0.052）差异无统计学意义。单因素和多因素分析；进展或转移的因素是初始前列腺特异性抗原。结论：我们的数据表明，在PFS中，RT优于RP，而远处转移相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊